Prediction markets reach 24 billion dollars a month as Kalshi adds drug trials

Twenty-four billion dollars cleared through prediction market platforms in a single month. That number, now on the public record, is the kind of figure that changes how a regulator reads a briefing.

The volume milestone arrived alongside Kalshi's move into cancer drug trial contracts — markets that let participants take positions on whether a specific therapy will clear a specific regulatory threshold. The two facts are not unrelated. Kalshi is filing into a volume story, and the drug trial contracts are the argument: that what the platform prices is information, not gambling, and that the distinction matters more as the numbers get larger.

The reporting says this is a product expansion story. I don't think that's where it lands. The drug trial contracts are a jurisdictional argument wearing a product announcement. Kalshi has spent the better part of eighteen months fighting state regulators who say its sports contracts are wagering under state law. The cancer trial markets are the counter-move — they are structurally difficult to classify as sports betting, they draw on a different regulatory tradition, and they sit in a space where information asymmetry is the whole point. A clinical-stage biotech employee and a retail trader are not equally positioned on an FDA advisory committee vote. That gap is what makes a market, and it is also what makes a regulator nervous.

The volume figure matters here in a way that goes beyond headline size. Twenty-four billion in monthly trading is large enough to attract capital that requires regulatory clarity as a condition of entry. Institutional money does not follow platforms through two-front legal wars on a handshake. What Kalshi is doing with the drug trial contracts — and with the public release of a volume number at this scale — is making the case that the platform has already arrived at a size where the question is no longer whether prediction markets exist in the United States, but under whose framework they operate.

Connecticut's court told Kalshi last week that a CFTC emergency order does not override a state court. Nevada is pursuing daily fines over geofencing failures Kalshi attributes to investigators who it says misrepresented their location. Novig filed against Wisconsin's attorney general over sports contracts on similar grounds. The legal map is fracturing state by state, and the drug trial expansion is Kalshi's answer to that fracture — a product line that sidesteps the sports-betting classification entirely and forces regulators onto less familiar terrain.

I have watched firms try this before: when the existing product is under pressure, move toward something the rules have not caught up to yet. It buys time. It does not always buy resolution. Whether the CFTC has issued guidance specific enough to cover clinical trial outcome contracts is not on the public record, and that gap is where the next fight will be argued.